Index

Acute HIV-1 infection and HIV-1 transmission, 109–127
Adler MW *see* **Weiss RA**
AIDS and the private sector, 83–85
Anti-retroviral therapy (ART) (*see also* HAART), 172, 182–184, 190, 193–200, 208
Antibody responses to vaccines, 212
Antimicrobial resistance (global) of *N. gonorrhoeae* and *Haemophilus ducreyi*, 145
Antiretroviral therapies (ART), 7,8, 9, 16
Asia (South and South East), demography, 73–78
Australasia, trends in the HIV pandemic, 15–16
Bacterial vaginosis (BV), 147–149
Bahamas, demography, 73–88
Behavioural interventions to prevent HIV infection: rapid evolution, increasing rigour, moderate success: **Bonell C, Imrie J**, 155–170
Blood transfusion and transmission, 9
Bonell C, Imrie J: Behavioural interventions to prevent HIV infection: rapid evolution, increasing rigour, moderate success, 155–170
Botswana, demography, 73–88
Breast-feeding, 99–100
Burchett S *see* **Goulder PJR**

Candidate HIV vaccines in clinical trials, 215–216
Carribean, trends in the HIV pandemic, 15
Case finding for STIs, 138–139
CCR for HIV entry into cells, 44–46
$CD4^+$ T-lyphocytes, 188–189
$CD8^+$
antiviral factor (CAF), 192
anti-HIV suppressor activity (CASA), 192
cytotoxic T-lymphocytes, 191–192
effector cells, 190–192
suppressor cells, 192
T-cell re-infusion, 198–199
Cell surface receptors (CCR), 43–59, 61–63, 69–70
Cell tropism and HIV
in immune and non-immune tissues, 47–49
HIV-1 receptors , 43–59
Central Asia, trends in the HIV pandemic, 15
China and STI/HIV, 130
Chronic asymptomatic HIV-1 infection, 65–69
Circumcision, protective effect of male, 9
Clade-specific vaccine design, 209
Clapham PR, McKnight A: HIV-1 receptors and cell tropism, 43–59
Co-receptor use in vivo, variation, 49–50
Co-trimoxazole, 181
Comprehensive care policy, planning and implementing, 178–182
Computer-assisted self-interview (CASI), 164
Condom protected sex, 141–143, 155
Core groups, 10
Cryptosporidium as OI, 193
CXCR co-receptors, 43, 44–49, 53, 54, 61, 69–70, 111
Cytomegalovirus (CMV), 193
Cytotoxic T-lymphocytes (CTLs), 62–71, 91–92, 94. 96–97, 119, 190–192
epitopes, 21, 30–36, 209
prevention of HIV infection, 213
responses, 213

DC-SIGN on dendritic cells, 43, 48, 52, 63, 114–115
Democratic Republic of the Congo (DRC), evolution of the M group virus in the , 23
Demography and economics of HIV/AIDS: **Whiteside A**, 73–88
Dependency ratio and orphaning, 80
Detours V *see* **Korber B**

East Asia and the Pacific, trends in the HIV pandemic, 14
Eastern Europe,
drug addicts, demography, 73–88
trends in the HIV pandemic, 15
Economics and demography of HIV/AIDS, 73–88
Epidemiology of
HIV/AIDS, global, 7–18
HIV/AIDS disease burden, 175–178
STIs, 130–131
Evolution of the M group virus in the Democratic Republic of the Congo (DRC), 23

© The British Council 2001

Evolutionary and immunological implications of contemporary HIV-1 variation: **Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V**, 19–42

Factors influencing susceptibility and resistance to HIV-1 infection, 112–114
Family planning (FP) clinics and STIs, 136, 144
Fertility, 79
Follicular dendritic cell (FDC) network, 119

Gaschen B *see* **Korber B**
Genetic factors, 112–113
Genital infection increases HIV-1 transmission, 111
Genital ulcer disease (GUD)
and HIV, 132
attributable to HSV-2 infection, 146
Gilks CF: HIV care in non-industrialised countries, 171–186
Global epidemiology HIV/AIDS: **Morison L**, 7–18
GM-CSF therapy, 198
Gonococcal antimicrobial susceptibility programme (GASP), 146
Gotch F *see* **Wilkinson J**
Goulder PJR, Jeena P, Tudor-Williams G, Burchett S: Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management, 89–108
gp120 interactions with co-receptors, 46–47, 62–64, 69–70
gp41 transmembrane, 44
Gram-negative sepsis, 180–181
Guyana, demography, 73–88

Haiti, demography, 73–88
Hanke T: Prospect of a prophylactic vaccine for HIV, 205–218
Hansasuta P, Rowland-Jones SL: HIV-1 transmission and acute HIV-1 infection, 109–127
Health promotion theory, 157–158
Herpes simplex virus (HSV), 132–133, 145–147, 149
Hierarchy of care, 182–184
Highly active anti-retroviral therapy/treatment (HAART), 15–16, 52, 90, 91,92, 98–101, 172, 182–184, 190, 193-200, 208
effect on OIs, 196–197
Highly exposed persistently seronegatives (HEPS), 113–114
History, modelling the, of the HIV epidemic through phylogenetics, 22–3
HIV (candidate) vaccines in clinical trials, 215–216
HIV and influenza compared, 29–30
HIV care in non-industrialised countries: **Gilks CF**, 171–186
HIV clades, importance of, 208–209
HIV in adult infection, successful control of, 91–92
HIV infection
behavioural interventions to prevent, 155–170
interventions against sexually transmitted infections (STI) to prevent, 129–153
paediatric, 89–108
HIV seroconversion studies, 133
HIV variation in different tissues, 51–52
HIV-1 infection
genetic subtypes, 23–5
factors influencing susceptibility and resistance to, 112–114
pathogenesis of , 61–72
HIV-1 receptors and cell tropism: **Clapham PR, McKnight A**, 43–59
HIV-1 transmission and acute HIV-1 infection: **Hansasuta P, Rowland-Jones SL**, 109–127
HIV-1 variants tropic for specialized cells in different tissues, 50–51
HIV-1 variation: evolutionary and immunological implications of contemporary, 19–42
HIV-infected immune system, 187–188
HIV–STI interactions, 131–133
HSV seropositive and HIV seroconversion, 133
HSV-related Bells palsy, 179
Human herpes virus 8 (HHV8) as OI, 193
Human papilloma virus (HPV) as OI, 193
IL-2 therapy, 198

Immune interventions: **Wilkinson J, Gotch F**
Immune-based therapies, 197–200
Immunological
and evolutionary implications of contemporary HIV-1 variation, 19–42
mechanisms of HIV resistance, 113–114
responses to a rapidly evolving pathogen, 30–7

Immunosuppression and opportunistic infections, 192–193
Implementing effective behavioural interventions in HIV prevention practice, 164–165
Imrie J *see* **Bonell C**
India, trends in the HIV pandemic, 13–14
Infectivity – what influences it? 111
Influenza and HIV compared, 29–30
Influenza vaccines: responding to change, 28–30
Information, education and communication (IEC) campaigns, 143
Injecting drug use (IDU), 9, 14
Integration of STI prevention and care in reproductive health services, 144–145
Interventions against sexually transmitted infections (STI) to prevent HIV infection: **Mayaud P, McCormick D,** 129–153
Introduction: **Piot P,** 3–5

Jeena P *see* **Goulder PJR**

Kenya, 132, 133
  breast-feeding in, 100
  sex-workers, resistance, 113
Kesmir C *see* **Korber B**
King Edward VIII Hospital (KEH) in Durban, South Africa, paediatric HIV care 89–108
Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V: Evolutionary and immunological implications of contemporary HIV-1 variation, 19–42

Late stage HIV-1 infection, 69–71
Latin America, trends in the HIV pandemic, 14
Life-expectancy, 78–79
Long-term
  non-progressors (LTNP), 91–92
  survival, 193

Macro-economic impacts, 82–83
Major histocompatibility complex (MHC). 61
Malawi, 132
  paediatric HIV infection, 91, 100
Male reproductive health services to control STIs, 145
Mannose-binding lectin (MBL), 113
Mass treatment of STIs, 139
Maternal and child health (MCH) clinics and STIs, 136,139,144
Mayaud P, McCormick D: Interventions against sexually transmitted infections (STI) to prevent HIV infection, 129–153
McCormick D *see* **Mayaud P**
McKnight A *see* **Clapham PR**
Mechanisms of progression to disease at different rates, 92–95
Memory cells, 190, 195, 200
MHC molecules, 189
Microsporidium as OI, 193
Middle-East, trends in the HIV pandemic, 13
MIP chemokines, 113
Modelling the history of the HIV epidemic through phylogenetics, 22–3
Models of AIDS, non-primate, 209–210
Morison L: The global epidemiology of HIV/AIDS, 7–18
Mortality, 75–78
Mother-to-child transmission (MTCT), 9–10, 16, 77–78, 89–90, 95–104, 112
Mwanza, Tanzania, STI control and HIV transmission, 133, 139–140
Mycobacterium avium complex (MAC), 198

Natural history of HIV/AIDS relevant to care, 172–175
Newly Independent States (NIS) of the former Soviet Union, 130
Non-industrialised countries: HIV care in, 171–186
Non-primate models of AIDS, 209–210
Non-syncytial (NSI slow/low), 69–70
North Africa,
  trends in the HIV pandemic, 13
North America,
  trends in the HIV pandemic, 15

Opportunistic infections (OIs), 175
  and immunosuppression, 192–193

Paediatric HIV care in Durban (SA), London (UK), and Boston (USA), 89–108
Paediatric HIV infection, correlates of protective immunity and global perspectives in prevention and management: **Goulder PJR, Jeena P, Tudor-Williams G, Burchett S,** 89–108
Paediatric HIV infection,
  augmenting, 97–99
  control of, 95–97

management of, 100–104
natural history, 90–91
prevention of, 99–100
Palliative care, 171,
Partner notification (PN), 136–137
Pathogenesis of HIV-1 infection: **Weber J**, 61–72
Peripheral blood mononuclear cells (PBMC), 69, 191
Phylogenetics, modelling the history of the HIV epidemic through , 22–3
Piot P: Introduction, 3–5
Pneumonia, 180–181
Population size and growth, 79–80
Pre-packages therapy (PPT) kits, 138
Preface: **Weiss RA, Adler MW & Rowland-Jones SL**, 1–2
Prevention of HIV infection and CTL, 213
Prevention of HIV infection by behavioural interventions, 155–170
Prevention stategy for HIV infection by interventions against sexually transmitted infections (STI), 129–153
Primary HIV infection (PHI), 62–65, 190, 194
clinical presentation of , 114–117
early events in, 114–116
immunopathological events in, 118–120
treatment of, 120
Primary prevention of STIs, 141–143
Primate lentiviruses, 21–2
Prophylactic vaccine for HIV, prospect of, 205–218
Prophylaxis for TB, 181
Prospect of a prophylactic vaccine for HIV: **Hanke T**, 205–218
Public health importance of sexually transmitted infections, 130–133

Rakai, Uganda and STI control, 139–140
RANTES
production, 113
recombinant form of, 53
Resistance and susceptibility to HIV-1 infection, 112–114
Rowland-Jones SL see **Hansasuta P** and **Weiss RA**
Russia, demography, 73–88

Screening for STIs, 138–139
Self-medication, 137
Sex workers, HIV-seropositive female in Ivory Coast, 132
Sexually transmitted infections (STI), 9, 11, 173
control programmes, 133–135
and HIV interactions, 131–133
interventions against, to prevent HIV infection, 129–153, 135–144
presumptive treatment, targeted periodic, 140–141
prevention, female-controlled, 142–143
Simian immunodeficiency virus (SIV)
monkey model of HIV, 21, 114–115, 119
model of acute infection, 190–192
Social psychological theories, 158
Sociological theories, 158–160
South Africa, 73–88, 100
South and South-East Asia, trends in the HIV pandemic, 13–14
Structured treatment interruptions, 196
Sub-Sahara Africa,
demography, 73–88, 89
paediatric HIV infection, 91, 93
trends in the HIV pandemic, 11–12
Subunit vaccine challenge experiments in non-human primates, 214–215
Supervised treatment interruption, 98
Susceptibility and resistance to HIV-1 infection, 112–114
Swaziland, demography, 73–88
Syncytial (SI fast/high), 69–70
Syndromic management of STI-associated ill-health, 135–136

Tanzania, demography, 73–88
Thai epidemic, 111
Thakallapally R see **Korber B**
Therapeutic vaccines, 199–200
Therapeutic vaccines, 216
Therapies
immune-based, 197–200
targeted at HIV receptors, 52–54
Transmission of HIV, 8–11
Transmission of HIV-1 and acute HIV-1 infection: routes and mechanism, 109–127
Transmission, mother-to-child (MTCT), 77–78, 89–90, 95–104, 112
Trends (global) in the HIV pandemic, 11–16
Tuberculosis
and HIV, 172, 173, 175, 178, 180–181
as AIDS-related illness, 12
Tudor-Williams G *see* **Goulder PJR**

Uganda, demography, 73–88

Vaccines for HIV, 114
paediatric HIV infection, 97–99
prospect of a prophylactic, 205–218
Vaccines
live-attenuated , 210
and long-term survival, 193
for STIs, 143
subunit, 210–212
therapeutic, 199–200
whole killed, 210
Vaginal microbicides, 142
Vitamin A deficency, increased HIV-1 transmission, 111
Voluntary counselling and testing (VCT), 171, 176, 180

Weber J: Pathogenesis of HIV-1 infection 61–72
Weiss RA, Adler MW, Rowland-Jones SL: Preface, 1–2
Western Europe, trends in the HIV pandemic, 15
Whiteside A: Demography and economics of HIV/AIDS, 73–88
WHO staging system, 173
Wilkinson J, Gotch F: Immune interventions, 187–203

Yusim K *see* **Korber B**

Zimbabwe, demography, 73–88
Zulu, South Africa, 93, 100